References
- Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviours of patients with acquired immunodeficiency syndrome in Thailand,1994–1998: regional variation and temporal trends. Clin Infect Dis 2001; 32: 955–62
- Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710–8
- van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15–21
- Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, Howe PA, White NJ. A, prospective study of AIDS-associated, cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect 2001; 43: 226–33
- Andes D, Stamsled T, Conklin R. Pharmacodynamics of amphotericin B in neutropenic mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45: 922–6
- Walsh TJ, Garrett K, Feurestein E, Girton M, Allende M, Bacher J, et al. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography: a novel, non-invasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother 1995; 39: 1065–9
- Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacother 2000; 20: 1335–55
- Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487–96
- Chabot GG, Pazdur, Valeriote FA, Baker LH. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci 1989; 78: 307–10
- Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses study Group. N Engl J Med 1999; 340: 764–71
- Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: randomized controlled trial. Br Med J 2001; 322: 579–82
- Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83–9
- Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003; 36: 943–51
- Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004; 54: 803–8
- Hiemenz JW. Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference?. Clin Infect Dis 2003; 36: 952–3
- Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75: 476–81
- Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 y of clinical experience. Rev Infect Dis 1990; 12: 308–28
- Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148: 2389–94
- Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures animal experiments and clinical study. J Infect Dis 2002; 186: 379–88
- Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of 3 different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995; 38: 459–65